ABUS ARBUTUS BIOPHARMA CORP revenue, earnings and financials

For the quarter ended June 30, 2026, ARBUTUS BIOPHARMA CORP reported revenue of $1.01M (down 90.6% from a year earlier), net income of −$5.14M and diluted EPS of −$0.03; over the last four quarters revenue was $182M and net income $153M; for the fiscal year ended December 2025 revenue was $14.1M, up 128.2% on the year before.

ABUS annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $14.1M, gross profit n/a, operating income −$38.2M, net income −$33.5M (margin -237.9%), EPS −$0.17
• Fiscal year ended Dec 2024: revenue $6.17M, gross profit n/a, operating income −$76.3M, net income −$69.9M (margin -1133.0%), EPS −$0.38
• Fiscal year ended Dec 2023: revenue $18.1M, gross profit n/a, operating income −$78.1M, net income −$72.8M (margin -401.6%), EPS −$0.44
• Fiscal year ended Dec 2022: revenue $39.0M, gross profit n/a, operating income −$65.5M, net income −$69.5M (margin -178.0%), EPS −$0.46
• Fiscal year ended Dec 2021: revenue $11.0M, gross profit n/a, operating income −$73.5M, net income −$76.2M (margin -693.9%), EPS −$0.83

ABUS quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $1.01M (down 90.6% year over year), net income −$5.14M, EPS −$0.03
• Quarter ended Mar 31, 2026: revenue $179M (up 10054.5% year over year), net income $170M, EPS $0.87
• Quarter ended Dec 31, 2025 (from the annual report): revenue $1.05M (down 33.2% year over year), net income −$3.76M, EPS −$0.01
• Quarter ended Sep 30, 2025: revenue $529K (down 60.5% year over year), net income −$7.74M, EPS −$0.04
• Quarter ended Jun 30, 2025: revenue $10.7M (up 522.2% year over year), net income $2.52M, EPS $0.01
• Quarter ended Mar 31, 2025: revenue $1.76M (up 15.1% year over year), net income −$24.5M, EPS −$0.13
• Quarter ended Dec 31, 2024 (from the annual report): revenue $1.57M (down 26.6% year over year), net income −$12.5M, EPS −$0.07
• Quarter ended Sep 30, 2024: revenue $1.34M (down 71.3% year over year), net income −$19.7M, EPS −$0.10
• Quarter ended Jun 30, 2024: revenue $1.73M (down 62.9% year over year), net income −$19.8M, EPS −$0.11
• Quarter ended Mar 31, 2024: revenue $1.53M (down 77.1% year over year), net income −$17.9M, EPS −$0.10
• Quarter ended Dec 31, 2023 (from the annual report): revenue $2.15M (down 65.7% year over year), net income −$19.3M, EPS −$0.12
• Quarter ended Sep 30, 2023: revenue $4.66M (down 21.7% year over year), net income −$20.1M, EPS −$0.12
• Quarter ended Jun 30, 2023: revenue $4.65M (down 67.3% year over year), net income −$17.1M, EPS −$0.10
• Quarter ended Mar 31, 2023: revenue $6.69M (down 46.8% year over year), net income −$16.3M, EPS −$0.10
• Quarter ended Dec 31, 2022 (from the annual report): revenue $6.25M (up 94.8% year over year), net income −$21.9M, EPS −$0.13
• Quarter ended Sep 30, 2022: revenue $5.95M (up 78.2% year over year), net income −$17.6M, EPS −$0.12
• Quarter ended Jun 30, 2022: revenue $14.2M (up 511.5% year over year), net income −$14.2M, EPS −$0.10
• Quarter ended Mar 31, 2022: revenue $12.6M (up 495.4% year over year), net income −$15.8M, EPS −$0.11
• Quarter ended Dec 31, 2021 (from the annual report): revenue $3.21M, net income −$21.3M, EPS −$0.15
• Quarter ended Sep 30, 2021: revenue $3.34M, net income −$19.2M, EPS −$0.24

ABUS cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$39.6M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$64.9M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$85.9M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$35.4M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$67.5M, share buybacks n/a

ABUS balance sheet

• Jun 30, 2026: cash $19.2M, total assets $274M, total liabilities $15.3M, shareholders' equity $259M
• Mar 31, 2026: cash $23.7M, total assets $277M, total liabilities $17.0M, shareholders' equity $260M
• Dec 31, 2025: cash $18.0M, total assets $94.6M, total liabilities $18.0M, shareholders' equity $76.6M
• Sep 30, 2025: cash $22.4M, total assets $97.7M, total liabilities $20.3M, shareholders' equity $77.4M
• Jun 30, 2025: cash $37.4M, total assets $103M, total liabilities $20.3M, shareholders' equity $83.0M
• Mar 31, 2025: cash $37.1M, total assets $117M, total liabilities $37.9M, shareholders' equity $79.2M
• Dec 31, 2024: cash $36.3M, total assets $132M, total liabilities $34.3M, shareholders' equity $97.4M
• Sep 30, 2024: cash $31.8M, total assets $140M, total liabilities $33.6M, shareholders' equity $107M

What is ABUS's revenue?

ARBUTUS BIOPHARMA CORP reported $182M of revenue over its last four quarters, through June 30, 2026.

Is ABUS profitable?

Yes. ARBUTUS BIOPHARMA CORP earned $153M over the last four quarters.

What is ABUS's EPS?

Diluted earnings per share over the last four quarters were $0.79; −$0.03 in the latest quarter.

ABUS ownership and insider trades · All stocks